Pierre Fabre étend sa collaboration avec Puma Biotechnology
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Partners of the Pierre Fabre Group: from health to beauty
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology | Evaluate
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Pierre Fabre engagements | NERLYNX
Accord entre Pierre Fabre et Puma Biotechnology
